References
- Engert A, Plutschow A, Eich HT, et al. Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma. N Engl J Med 2010;363:640–652.
- Eich HT, Diehl V, Görgen H, et al. Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: final analysis of the German Hodgkin Study Group HD11 trial. J Clin Oncol 2010;28:4199–4206.
- Matasar MJ, McCallen LN, Reidel ER, et al. Late mortality and morbidity of patients with Hodgkin lymphoma treated in adulthood. J Clin Oncol 2009;27(15 Suppl.): Abstract 8547.
- Wirth A, Grigg A, Wolf M, et al. Risk and response adapted therapy for early stage Hodgkin lymphoma: a prospective multicenter study of the Australian Leukaemia and Lymphoma Group/Trans-Tasman Radiation Oncology Group. Leuk Lymphoma 2011;52:786–795.
- Aleman BM, van den Belt-Dusebout AW, Klokman WJ, et al. Long-term cause-specific mortality of patients treated for Hodgkin's disease. J Clin Oncol 2003;21:3431–3439.
- Straus D, LaCase A, Juweid M, et al. Doxorubicin, vinblastine and gemcitabine (AVG), a novel regimen for the treatment of early stage Hodgkin lymphoma (HL): results of CALGB 50203. Blood 2007;110(Suppl. 1): Abstract 214.
- Rueda Dominguez A, Marquez A, Guma J, et al. Treatment of stage I and II Hodgkin's lymphoma with ABVD chemotherapy: results after 7 years of a prospective study. Ann Oncol 2004;15:1798–1804.
- Canellos GP, Abramson JS, Fisher DC, et al. Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy. J Clin Oncol 2010;28:1611–1615.
- Meyer RM, Gospodarowicz MK, Connors JM, et al. Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National Cancer Institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group. J Clin Oncol 2005;23:4634–4642.